New study analyzes Odevixibat's impact on rare liver disease outcomes
NCT ID NCT07497724
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 3 times
Summary
This study looks at a rare liver disease called PFIC, which causes severe itching and liver damage. Researchers compare patients who took the drug odevixibat to those who did not, using data from past studies and a patient registry. The goal is to see if odevixibat helps avoid liver transplants or death over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PFIC - PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Not applicable - retrospective secondary use of data
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.